A Phase 2 dose ranging study of ATI-50001 for the oral treatment of alopecia totalis and alopecia universalis

Trial Profile

A Phase 2 dose ranging study of ATI-50001 for the oral treatment of alopecia totalis and alopecia universalis

Planning
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs ATI 50001 (Primary)
  • Indications Alopecia areata
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Nov 2017 According to an Aclaris Therapeutics media release, the company is planning to initiate this trial in the first half of 2018.
    • 15 Mar 2017 According to an Aclaris Therapeutics media release, the company is planning to initiate this trial in the second half of 2017.
    • 16 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top